Most Clicked StoriesMore >
Human-gene patent ruling could hurt pharma, gene-testing industry
BIO SmartBrief | Jun 14, 2013
The Supreme Court's decision Thursday that naturally occurring human genes can't be patented could have broad implications for the pharmaceutical, biotech and gene-testing industries. Critics said the ruling would not only hurt Myriad Genetics, but also the bottom line of companies that sell genetic tests. It could also discourage investment in genetic sequencing research. "The Supreme Court's decision today represents a troubling departure from decades of judicial and Patent and Trademark Office precedent," BIO President and CEO Jim Greenwood said. Denver Post, The (06/13) Reuters (06/14) HealthDay News (06/13) Yahoo (06/13)
215 cardiovascular disease drugs in the pipeline, report finds
BIO SmartBrief | Jun 13, 2013
Biotech startup lands $11M to develop pioneering anticoagulant
BIO SmartBrief | Jun 17, 2013
FDA tweaks orphan drug rules
BIO SmartBrief | Jun 14, 2013
Questcor buys U.S. rights to Novartis autoimmune/inflammatory drug
BIO SmartBrief | Jun 12, 2013
FTC can challenge "pay-for-delay" arrangements, top court says
BIO SmartBrief | Jun 18, 2013
Study quantifies the Human Genome Project's huge economic impact
BIO SmartBrief | Jun 13, 2013
Don't misuse patents to curb market entry of biosimilars
BIO SmartBrief | Jun 17, 2013
Flaws found in study linking biotech feed to poor pig health
BIO SmartBrief | Jun 13, 2013
Immune Design partners with 2 nonprofits on cancer immunotherapy
BIO SmartBrief | Jun 14, 2013
Find BIO SmartBrief Issues by Date:
BIO News
More >
Secure document sharing services optimized for life science organizations
BIO SmartBrief | Jun 19, 2013
Save on energy costs through BIO's newest cost-savings program
BIO SmartBrief | Jun 18, 2013
April 2013 BIO therapeutic newsletters
BIO SmartBrief | Jun 17, 2013
Industrial biotechnology with a French twist!
BIO SmartBrief | Jun 14, 2013
Sign up for BIO SmartBrief
